CARDIOUSGHIFU

En cours

High Intensity Focused Ultrasound (HIFU) has been gaining increasing interest in the medical and scientific community for a number of years. By focusing the ultrasound in the human body, it is possible to coagulate tissues in a small, perfectly focused focal area without damaging the surrounding tissue. Thanks to recent technological advances, several medical devices have been developed, allowing the clinical treatment of benign and malignant tumors of the prostate, liver, kidney, uterus, breast and pancreas, but to date the Cardiac applications have remained little explored. In the context of the treatment of cardiac arrhythmias, a real public health problem, the HIFU could nevertheless offer original therapeutic solutions with significant advantages over current approaches such as surgery or radiofrequency catheter ablation. Indeed, the HIFU can very precisely create thermal lesions in heart tissue at perfectly controlled depths allowing in particular the complete removal of the wall of the heart. In addition, HIFUs can be combined with real-time ultrasound imaging modalities, such as standard echocardiography modes or newly developed modalities such as shear wave imaging, which can be used to monitor treatments in real time. thermal ablation and quantitatively image the generated thermal lesion. However, the thermal ablation of cardiac tissues presents to date enormous technological challenges. The main reasons for these challenges are the difficulty of targeting cardiac tissues (and in particular right and left atria) with low-invasiveness HIFU devices, the complex geometry of cardiac cavities and rapid heart movements. Most of the approaches developed for other organs have thus proved ineffective on the heart, highlighting the need to develop specific approaches. The objective of this project is to develop innovative, reliable and effective approaches for the clinical treatment of cardiac arrhythmias based on the use of ultrasound-guided HIFU. Two promising and minimally invasive approaches will be developed in this project: a first based on the use of transesoshageal HIFU, and the second on the use of an intracardiac HIFU catheter. These two approaches coupled with guidance and monitoring by ultrasound imaging will eventually allow the removal of cardiac tissue. It is the combination of the four project partners, all internationally recognized in their fields, that will create the necessary synergy for this ambitious project: Vermon is a world leader in the design and manufacture of ultrasound transducers, INSERM U1032 LabTau is specialist development of minimally invasive ultrasound therapeutic applications, Langevin Institute is recognized for its expertise in wave physics and in the field of new modalities of imaging and medical therapy, and LTSI INSERM U642 in the field of image processing. In addition, thanks to the collaboration of two major clinical teams pioneers in the field of cardiac arrhythmias and ablation (teams of Prof. Haissaguerre in Bordeaux, and Prof. Chevalier in Lyon), this project will be led to the stage. of preclinical validation on the animal of the prototypes of therapy.

Retombées du projet

Produit / Prototype : 8

Emplois crées : 16

Emplois maintenus : 24

Publication scientifique : 84

Thèse : 16

Rapport final : 4

Brevet : 4

Personnes engagées sur le projet
Informations sur le projet

Début du projet le 11 / 05 / 2021 | Fin du projet le 11 / 05 / 2021


Domaines d'activité stratégiques

Matériaux et composants pour l'électronique

Ces projets pourraient vous intéresser

Retour aux projets

Consulter les appels à projets

Vous avez une idée de projet à développer ?

Découvrez les appels à projets

Je souhaite être accompagné !

Besoin d'un accompagnement pour vos projets ?

Demande d'adhésion